DNage to Participate in European Study on Biomarkers of Ageing

LEIDEN, NETHERLANDS--(Marketwire - July 14, 2008) - Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage is participating in a large European study, called MARK-AGE, to identify and establish biomarkers of human ageing. Under the Seventh Research Framework Programme (FP7), the European Union has allocated a total budget of almost EUR 12 million for this study for a period of five years.